Administration of a standardized plasma-protein solution (Biseko®) in high-risk patients with systemic inflammatory response syndrome: influence on cytokine levels and survival

Therapeutic Solutions of Human Albumin – The Possible Effect of Process-Induced Molecular Alterations on Clinical Efficacy and Safety

“…Nevertheless, as outlined above, oxidised forms of albumin abound in albumin solutions, while one commercial product formulated without N-AcTrp had a higher level of reduced albumin, and a superior antioxidant capacity, than competitor products (111). A stabilised formulation of human serum, present on the market for many years (175), has been shown to retain albumin's capacity to bind drugs, in contrast to purified albumin products (114) and also shows superior invitro properties in some systems (176,177) as well as superior anti-inflammatory effects and a survival benefit in patients with systemic inflammatory response syndrome (178). This product is virally inactivated with a different technology (β-propiolactone treatment and ultra violet irradiation) than pasteurisation, and therefore lacks the stabilisers found in albumin solutions.…”